Emerging treatment options for prostate cancer
Prostate cancer treatment has rapidly evolved in the past few years. Androgen deprivation therapy has been the backbone of treatment for locally advanced and metastatic prostate cancer, but increme…
Related Articles
Signaling new therapeutic opportunities: cytokines in prostate cancer
Despite FDA approval of sipuleucel-T in 2010, endeavors to use immune checkpoint inhibitors in unselected prostate cancer patients have not improved clinical outcomes. These efforts…
Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Restaging With Prostate-Specific Membrane Antigen Imaging in Metastatic Castration-Resistant Prostate Cancer: When Seeing More Is Detrimental to Care
#PSMA is amazing new tech but is using it to expedite the call of disease progression helping #ProstateCancer patients?
Biochemically recurrent prostate cancer in the era of… : Current Opinion in Oncology
egies and emerging therapeutic data. Managing BCR requires a unique perspective in oncology that balances toxicities and disease kinetics. Recent findings Prostate specific membrane antigen…
Thio-2 inhibits key signaling pathways required for the development and progression of castration resistant prostate cancer.
Abstract. Therapies that abrogate persistent androgen receptor (AR) signaling in castration resistant prostate cancer (CRPC) remain an unmet clinical need. The N-terminal domain (NTD) of…
Physician-Scientist Early Investigator Program | Center for Cancer Research
CCR’s Physician-Scientist Early Investigator Program (PEIP) is a highly competitive opportunity intended for physicians dedicated to laboratory bench-to-bedside or clinic-based research. This position is in…
With New Technology Comes Great Responsibility: Prostate-Specific Membrane Antigen Imaging in Recurrent Prostate Cancer
w/out clinical context #PSMA PET imaging may lead to substantial over treatment in pts w/recurrent #ProstateCancer
Randomized, Double-Blind, Placebo-Controlled Phase III Trial Comparing Docetaxel and Prednisone With or Without Bevacizumab in Men With Metastatic Castration-Resistant Prostate Cancer: CALGB 90401
Purpose A randomized, placebo-controlled study based on preclinical and clinical data that supports the potential role of vascular endothelial growth factor in prostate cancer was…
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer – Full Text View – ClinicalTrials.gov
M9241 in Combination With Docetaxel in Adults With Metastatic Castration Sensitive and Castration Resistant Prostate Cancer – Full Text View.